tbuckley/cabot-search huggingface dataset:
Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB)
Authors: Meera Yogarajah, Phuong L. Nguyen, Rong He, Hassan B. Alkhateeb, Mithun Vinod Shah, Mrinal M Patnaik, Kebede H. Begna, Michelle A Elliott, Naseema Gangat, William J Hogan, Ayalew Tefferi, Mark Litzow, Aref Al-Kali
Journal: Blood (2019)
Targeted Next Generation Sequencing Reveals Molecular Heterogeneity in Non-CLL Clonal B-Cell Lymphocytosis
Authors: Irene Defrancesco, Silvia Zibellini, Emanuela Boveri, Marco Frigeni, Virginia Valeria Ferretti, Ettore Rizzo, Francesca Capuano, Arturo Bonometti, Chiara Candido, Sara Rattotti, Elena Flospergher, Fabio Bergamini, Caterina Zerbi, Marco Paulli, Marzia Varettoni, Luca Arcaini
Journal: Blood (2019)
Whole Exome Sequencing in Children with Sickle Cell Anemia Who Developed Ischemic Stroke Prior to 4 Years of Age Reveals a Strong Association with Inherited Dyslipidemias
Authors: John N. Brewin, Riley Cook, Alexander E Smith, Valentine Brousse, Julie Brent, Sanjay Tewari, Baba PD Inusa, Stephan Menzel, David C Rees
Journal: Blood (2019)
Future Management of Infectious Diseases
Authors: R. Lamb
Journal: BMJ (1964)

BRnIsHpermitted left-heart catheterization with a catheter of the sime calibre as that introduced at the femoral artery.Perhaps Drs.Ikram and Nixon could give more information on this point, and also as to whether the cathe- ters were of a bore sufficient for adequate angiocardiography.In our series the catheter used has (almost invariably) been the grey Kifa-Odman (O.D. = 2.8 mm.: I.D. = 1.8 mm.).A smaller bore catheter is not adequate in our hands for the performance of left angiocardiography in the adult.-Iam, etc.,
Predictive Significance of Selected Gene Mutations Identified Using Next Generation Sequencing in Relapsed and Refractory Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib
Authors: Marcin M Machnicki, Patryk Górniak, Monika Pepek, Agnieszka Szymczyk, Elżbieta Iskierka-Jażdżewska, Pawel Steckiewicz, Aleksandra Bluszcz, Malgorzata Rydzanicz, Marek Hus, Rafal Ploski, Przemyslaw Juszczynski, Tomasz Stoklosa, Krzysztof Jamroziak, Bartosz Pula
Journal: Blood (2019)
The Monocle Sign in FDG-PET
Authors: Erika Orita, Christian M. Meerwein, Daniele A. Pizzuto, Paul Stolzmann, Martin W. Huellner
Journal: Clinical Nuclear Medicine (2019)

Abstract We report three cases of unilateral 18 F-FDG uptake in the orbicularis oculi muscle in subjects with contralateral peripheral facial nerve palsy. We argue that this asymmetric uptake pattern in fact reflects lack of metabolism on the side affected by facial nerve palsy, owing to denervation. Since the unilateral periorbital uptake resembles a monocle, we chose to call this finding the monocle sign. The monocle sign should not be confused with inflammation or tumor, but should prompt a neurological assessment for facial nerve palsy and a potential underlying disease.
SURG-16. SUPRATOTAL VERSUS GROSS TOTAL RESECTION OF GLIOBLASTOMA: A SYSTEMATIC REVIEW
Authors: Christina Jackson, John Choi, Carrie Price, Chetan Bettegowda, Michael Lim, Gary Gallia, Jon Weingart, Henry Brem, Debraj Mukherjee
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Due to the infiltrative nature of glioblastoma(GBM) outside of the contrast enhancing region in the peritumoral zone, there is increasing movement to perform supratotal resections (SpTR) by extending the edge of resection beyond the contrast enhancing portion of the tumor. However, there is currently no consensus on the potential survival benefit of SpTR in GBM as compared to gross total resection (GTR). METHODS Therefore, we performed a systematic review using PRISMA guidelines and performed a comprehensive literature search on Pubmed, EMBASE, The Cochrane Library, Web of Science, Scopus, and ClinicalTrials.gov, from inception to August 16, 2018, to identify articles comparing overall survival (OS) after SpTR versus GTR. Furthermore, we assessed study quality using the Oxford Centre for Evidence-Based Medicine guidelines. RESULTS We identified 8902 unique citations, of which 11 articles and 2 abstracts met study inclusion criteria. 925 patients underwent SpTR out of a total of 2137 patients. 9 of the 13 studies demonstrated improved survival with SpTR compared to GTR (median improvement in OS of 10.5 months), with no significant difference in post-operative complication rate. Conversely, one abstract found worsened outcomes with SpTR compared to GTR (median decrease in OS of 4 months). However, overall study quality was poor, with 12 of the 13 studies of level IV evidence and one study of level IIIb evidence. We were unable to perform a meta-analysis due to significant clinical and methodological heterogeneity amongst the studies (e.g. differences in adjuvant therapy and lack of standardization of definition of supratotal resection). CONCLUSIONS Our systematic review indicates that SpTR may be associated with improved OS compared to GTR for GBM. However, this is limited by poor study quality and significant clinical and methodological heterogeneity amongst the studies. There is need for prospective clinical trials to further establish standardized guidelines for SpTR in GBM.
Splenic Marginal Zone Lymphoma: Risk of Transformation, Clinico-Biological Features at Transformation and Prognosis
Authors: Gabriela Bastidas, Silvia Bea, Alba Navarro, Eva Gine, Julio Delgado, Tycho Baumann, Alfredo Rivas-Delgado, Laura Magnano, Neus Villamor, Dolors Costa, Colomer Dolors, Monica Lopez-Guerra, María Rozman, Daniel Martínez, Balagué Olga, Maria Joao Baptista, Miguel Alcoceba, Lourdes Escoda, Andrew Wotherspoon, Elias Campo, Armando Lopez-Guillermo, Estella Matutes
Journal: Blood (2019)
INNV-19. SURVEYING BIAS IN NEURO-ONCOLOGY AND SOCIETY FOR NEURO ONCOLOGY (SNO) MEMBERS: GENDER AND BEYOND
Authors: Priya Kumthekar, Priscilla Brastianos, Erin Dunbar, Katherine Peters, Alyx Porter
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND The face of neuro-oncology providers has evolved over the century. We sought to evaluate if its culture has evolved concurrently. Women in NeuroOncology (“WiN.”) is a SNO subcomittee that identifies the needs of women in neuro-oncology and promotes advancement of the careers of women in neuro-oncology. We created this survey to examine bias within our field with the goal to implement future change. METHODS Following IRB approval, we surveyed both male and female SNO members and analyzed de-identified responses. RESULTS Of the 206 respondents, 25% identified as male, 84.9% were in academics, 73.7% were primarily research focused (69% clinical), and 59% were medical neuro-oncology focused. The majority of respondents were 36–45 years old (47%), followed by 46–55 (32%), and 21% aged 56+. 69.8% self-identified as white, followed by 22% Asian, 7.8% Latin, and 2.9% Black. The majority reported general professional bias at least “not infrequently”, with 11.7% reporting it “very commonly.” 59.9% reported “not being invited to participate and or being considered for an opportunity”, followed by 46.1% “being minimized, teased or disrespected”, 44.3% “being passed over for professional opportunities”, and 41.9% salary disparity. Furthermore, of those reporting general professional bias, 42.9% reported a lack of effective mentorship and 94% reported some frequency of burnout, with 34% “commonly, very commonly”, followed by 28.3% “not infrequently.” Notably, although only 25% of responders were men, 82.4% of total respondents reported some frequency of gender bias in the workplace, with “not infrequently” being the most commonly reported (48%). CONCLUSIONS In this survey, we identified SNO members who have experienced bias. Based on quantitative and qualitative responses, many reported bias manifesting as missing academic opportunities, salary disparity, burnout, and lack of mentorship. As we cultivate the next generation, we will use these results to engage those in leadership to promote unbiased equality.
Title - Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); Long Term Second Primary Malignancy (SPM) Incidence in the Context of Lenalidomide Maintenance
Authors: John R Jones, David Cairns, Charlotte Pawlyn, Faith E. Davies, Rachel Sigsworth, Matthew Jenner, Martin F. Kaiser, Rebecca Mottram, Mark T Drayson, Gordon Cook, Walter M Gregory, Roger G. Owen, Kevin Boyd, Graham Jackson, Gareth Morgan
Journal: Blood (2019)
RARE-17. PRIMARY DIFFUSE LEPTOMENINGEAL GLIOMATOSIS OF HIGH GRADE TUMORS
Authors: Ji-Eyon Kwon, Gyung-Oh Ko, Gi Hwan Hwang, In Ah Kim, Chan Woo Wee, Yu Jung Kim, Gheeyoung Choe, Byung-Se Choi, Jung Ho Han, Chae-Yong Kim
Journal: Neuro-Oncology (2019)

Abstract Primary diffuse leptomeningeal gliomatosis(PDLG) of high grade glioma(HGG) is a rarely documented phenomenon observed in less than 5% of glioblastoma(GBM). Purposes of this study are to investigate the clinical outcomes of PDLG of HGG and to analyze the results according to the procedures of operations. We retrospectively reviewed the medical records of 469 patients of HGG at our institute between 2004 and 2019 and 9 of who with PDLG were enrolled in our study. These 9 patients satisfying the condition of Karnofsky performance status ≥70 and Eastern Cooperative Oncology Group performance status ≤2 were conducted the primary surgical biopsy with or without intracranial pressure control. All patients finished the surgery within about 11 days after the detection of leptomeningeal seeding(LMS) on preoperative MRI images and completed the concurrent chemoradiotherapy(CCRT) with temozolomide(TMZ). Among 9 patients, 7 patients started adjuvant temozolomide and 3 patients completed the six cycles of it. 7 patients had done ICP control operation such as ommaya reservoir insertion, extraventricular drainage, and ventriculoperitoneal shunt within 23.3 days after defined as PLDG and survived nearly 10 months. Their pathologic findings were turned out to be seven glioblastomas and two anaplastic astrocytomas. Their median overall survival was 14 months and the 1- and 2-year overall survival rates were 50.8±17.7% and 16.9±15%, respectively. Compared to the 10-year study of GBM in the same institute between 2004 and 2011, in which 67 patients finished with CCRT with TMZ, the median overall survival was 19 months and the 1- and 2-year overall survival rates were 78.3% and 41.7%. The results indicate that PLDG has a worse outcome and overall survival rate is lower than GBM without LMS, so the earlier start of standard CCRT right after aggressive control of increased ICP like conducting CSF diversion might be helpful for the elongation of life expectancy.
Molecular Mechanism for Synergistic Anti-Leukemic Activity of Tyrosine Kinase Inhibitors and Glucocorticoids Against Ph+ALL
Authors: Meixian Huang, Takeshi Inukai, Keiko Kagami, Masako Abe, Tamao Shinohara, Atsushi Watanabe, Koshi Akahane, Shinpei Somazu, Hiroko Oshiro, Kumiko Goi, Yasuhiro Maeda, Seiichi Okabe, Shinya Kimura, Kanji Sugita
Journal: Blood (2016)
The Effect of Diagnostic Wait Time on the Survival of Patients with Diffuse Large B-Cell Lymphoma Differs Depending on International Prognostic Index
Authors: Shin Lee, Negoro Eiju, Morishita Tetsuji, Kei Fujita, Hideaki Yamauchi, Kana Oiwa, Takanori Ueda, Takahiro Yamauchi
Journal: Blood (2019)
Glutathione plays an important role in tumor microenvironment-mediated drug resistance in chronic lymphocytic leukemia
Authors: Wan Zhang, Dunyaporn Trachootham, Jan Burger, Michael Keating, Peng Huang
Journal: Cancer Research (2008)

685  Chemotherapy agents such as fludarabine and cyclophosphamide are important drugs used in the treatment of chronic lymphocytic leukemia (CLL). Unfortunately, development of drug resistance in CLL represents a major challenge in clinical treatment of this disease. The facts that CLL cells survive and accumulate in vivo but rapidly die in culture indicate the importance of microenvironment to sustain the survival of CLL cells. Tumor microenvironment is also thought to play a critical role in cellular sensitivity to anticancer agents. In our study, we observed that extracellular glutathione (GSH) added to the culture of leukemia B-cells isolated from CLL patients protect the CLL cells from apoptosis in vitro. Because cellular GSH decrease rapidly in B-CLL cells in vitro, we tested the hypothesis that proper microenvironment is critical in maintaining the GSH level in B-CLL cells and confers cell survival advantage and drug resistance. Comparison of intracellular GSH in B-CLL cells cultured alone and co-cultured with human bone marrow stromal cells showed that the GSH level was significantly higher in the co-culture system, whereas the levels of GSH in the medium were similar under both culture conditions. CLL cells showed a significantly better viability and were resistant to F-ara-A (active form of fludarabine) when co-cultured with bone marrow stromal cells. This data indicate that, rather than secrete and provide extracelluar GSH to B-CLL cells, the stromal cells likely provide a factor that signals B-CLL cells to maintain a high level of GSH and promotes cell survival and drug resistance. Depletion of GSH in CLL cells by β-phenylethyl isothiocyanate (PEITC) abrogated the protective effect of the stromal cells under the co-culture conditions. To evaluate the nature of this protective factor, experiments using transwell apparatus showed that the bone marrow stromal cells seemed to produce soluble factor(s) to upregulate GSH synthesis in B-CLL cells. Our study suggests a novel role of GSH in promoting CLL cell survival mediated by bone marrow stromal factor(s), and a feasibility to overcome drug resistance using proper agents such as PEITC.
Prevention of Dust Diseases of the Lung
Authors: C. M. Fletcher
Journal: BMJ (1948)

It is wrong to assume that intercapillary glomerulosclerosis is only found in the elderly.In our present series of 16 cases (9 with necropsy confirmation) we have patients aged 47, 42, 31, 40, 42, 39, and 33.The first three of these have died and the characteristic lesion has been found.The 31-year-old patient had had diabetes for 21 years.Most of these cases have been seen by us through the courtesy of Professor T. H. Oliver, at whose diabetic clinic they have attended.-We are, etc.,
Current perspectives on the role of interleukin-1 signalling in the pathogenesis of asthma and COPD
Authors: Emmanuel T. Osei, Corry-Anke Brandsma, Wim Timens, Irene H. Heijink, Tillie-Louise Hackett
Journal: European Respiratory Journal (2019)

Asthma and chronic obstructive pulmonary disease (COPD) cause significant morbidity and mortality worldwide. In the context of disease pathogenesis, both asthma and COPD involve chronic inflammation of the lung and are characterised by the abnormal release of inflammatory cytokines, dysregulated immune cell activity and remodelling of the airways. To date, current treatments still only manage symptoms and do not reverse the primary disease processes. In recent work, interleukin (IL)-1α and IL-1β have been suggested to play important roles in both asthma and COPD. In this review, we summarise overwhelming pre-clinical evidence for dysregulated signalling of IL-1α and IL-1β contributing to disease pathogenesis and discuss the paradox of IL-1 therapeutic studies in asthma and COPD. This is particularly important given recent completed and ongoing clinical trials with IL-1 biologics that have had varying degrees of failure and success as therapeutics for disease modification in asthma and COPD.
Smoking and Lung Cancer
Authors: R. Doll, A. B. Hill
Journal: BMJ (1953)

later, whereas in 20 with a history of severe cerebral acci- dent before operation 9 developed them later.Similarly in 784 patients without severe myocardial disease there was no subsequent coronary thrombosis, whereas in 18 patients with severe myocardial damage there was one post-operative coronary thrombosis.Spinal cord damage occurred in two others, and this was a serious matter.In expert hands, however, this complication should reach a low irreducible minimum.Contraindications to inducing hypotension were (1) myo- cardial disease; (2) arteriosclerosis, whether local or general- ized; (3) a history of previous cerebral vascular accident; (4) anaemia, chronic pulmonary disease, congestive heart failure, and other conditions affecting oxygen transport; and (5) malignant hypertension.The only indication for hypotension was when its advantages to the patient and the surgeon were definite and were likely to outweigh the accepted risks.
Passion fruit-like exosome-PMA/Au-BSA@Ce6 nanovehicles for real-time fluorescence imaging and enhanced targeted photodynamic therapy with deep penetration and superior retention behavior in tumor
Authors: Shaojun Pan, Lijia Pei, Amin Zhang, Yuhui Zhang, Chunlei Zhang, Mark Huang, Zhicheng Huang, Bin Liu, Lirui Wang, Lijun Ma, Qian Zhang, Daxiang Cui
Journal: Biomaterials (2019)
Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Authors: Wilson I Gonsalves, Srinivas Devarakonda, Rachid Baz, Natalia Neparidze, Alex A Adjei, Charles Kunos, Shaji K. Kumar
Journal: Blood (2019)
USP22 Functions as an Oncogenic Driver in Prostate Cancer by Regulating Cell Proliferation and DNA Repair
Authors: Jennifer J. McCann, Irina A. Vasilevskaya, Neermala Poudel Neupane, Ayesha A. Shafi, Christopher McNair, Emanuela Dylgjeri, Amy C. Mandigo, Matthew J. Schiewer, Randy S. Schrecengost, Peter Gallagher, Timothy J. Stanek, Steven B. McMahon, Lisa D. Berman-Booty, William F. Ostrander, Karen E. Knudsen
Journal: Cancer Research (2019)

Emerging evidence indicates the deubiquitinase USP22 regulates transcriptional activation and modification of target substrates to promote pro-oncogenic phenotypes. Here,
Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency
Authors: Audra N. Boscoe, Yan Yan, Elizabeth Hedgeman, Eduard J. van Beers, Hanny Al-Samkari, Wilma Barcellini, Stefan W. Eber, Bertil Glader, Hassan M. Yaish, Satheesh Chonat, Jennifer A. Rothman, Mukta Sharma, Nina Kollmar, Christine M. Knoll, Kevin H. M. Kuo, Janet L. Kwiatkowski, Yves D. Pastore, Alexis A Thompson, Yaddanapudi Ravindranath, Ellis J. Neufeld, Heng Wang, Susanne Holzhauer, Vicky R. Breakey, Madeleine M. Verhovsek, Joachim B. Kunz, Sujit Sheth, Melissa A. McNaull, Melissa J. Rose, Dagmar Pospisilova, Jenny M. Despotovic, Rachael F. Grace
Journal: Blood (2019)
HIV Prevention and Treatment Scale-up and Community HIV Incidence in KwaZulu-Natal, South Africa
Authors: Xiangrong Kong
Journal: JAMA Network Open (2019)

Ayesha B. M. Kharsany, PhD; Cherie Cawood, MBA; Lara Lewis, MSc; Nonhlanhla Yende-Zuma, PhD; David Khanyile, BA; Adrian Puren, PhD; Savathree Madurai, PhD; Cheryl Baxter, PhD; Gavin George, PhD; Kaymarlin Govender, MPhil; Sean Beckett, MS; Natasha Samsunder, MMedSci; Carlos Toledo, PhD; Kassahun Abere Ayalew, MPhil; Karidia Diallo, PhD; Mary Glenshaw, PhD; Amy Herman-Roloff, PhD; Eduan Wilkinson, PhD; Tulio de Oliveira, PhD; Salim S. Abdool Karim, PhD; Quarraisha Abdool Karim, PhD
Targeted Mass Spectrometry-Based Serum M-Protein Monitoring for Early Relapse Detection
Authors: Zac McDonald, Mariya Liyasova, Paul Taylor, Xin Xu, Kathleen Gorospe, Chenyu Yao, Qixin Liu, Liqiang Yang, Bin Ma, Jesus Piza, Donna E Reece, Suzanne Trudel
Journal: Blood (2019)
GERM-01. RECURRENCE PATTERN AND SURVIVAL FOR RELAPSED INTRACRANIAL NON-GERMINOMATOUS GERM CELL TUMORS: A SINGLE-INSTITUTION EXPERIENCE
Authors: Lei Wen
Journal: Neuro-Oncology (2021)

Abstract Purpose Intracranial non-germinomatous germ cell tumors (NGGCTs) have lower overall survival than germinoma because relatively higher recurrence usually occurs after first line therapy. Methods Between January 2003 and December 2018, 111 consecutive patients diagnosed with NGGCTs reviewed. Those who progressed after first line therapy were included in this study. Data of first line treatment, salvage treatment, clinicopathological features and survival were collected and analyzed. Results Totally, thirty patients (30/111, 27.0%) relapsed in our cohort, including 19 patients with accurate relapse information detail, and 11 patients who died of disease progression during follow up but without exact time and site of relapse. The median OS from diagnosis of the disease was 49.2 months (95% CI: 14.1 to 84.3 months) and 3-year OS was 54.3%. Patients who received both CSI and chemotherapy relapsed less than those who received reduced volume of radiotherapy or only CSI or only chemotherapy (22.5% vs. 45.5%, p=0.034). Of 19 patients who had detail information of recurrence time and site, the median time from diagnosis of disease to relapse was 9.5 months (2.2 to 72.1 months). Regarding to recurrence site, most patients relapsed in primary site (10/19, 52.6%) or distant intracranial (6/19, 31.6%). The recurrence site of other 3 patients were spinal (n=1), ventricular (n=1) and peritoneal (n=1). Conclusion Protracted follow-up is recommended because late recurrence is not uncommon. Primary tumor site and distant intracranial are the most prevalent relapsed location. Patients who relapsed could benefited from both CSI and salvage chemotherapy.
Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression
Authors: Mariko Ishibashi, Ryosuke Kinoshita, Koiti Inokuchi, Hiroshi Handa, Makoto Sasaki, Norio Komatsu, Yoichi Imai, Norina Hiroike, Junji Tanaka, Sakae Tanosaki, Shigeki Ito, Mika Sunakawa, Toshio Asayama, Yasuko Kuribayashi-hamada, Rimpei Morita, Hideto Tamura
Journal: Blood (2019)
A Transcriptomic Continuum of Differentiation Arrest in Acute Leukemia
Authors: Jonathan Bond, Aleksandra Krzywon, Ludovic Lhermitte, Christophe Roumier, Anne Roggy, Mohamed Belhocine, Alexander Kheirallah, Patrick Villarese, Guillaume Hypolite, Francine Garnache-Ottou, Herve Dombret, Nicolas Boissel, Claude Preudhomme, Vahid Asnafi, Elisa Laurenti, Elizabeth Macintyre
Journal: Blood (2019)
A Systematic Review and Meta-Analysis of Cardio-Vascular Side Effects with Fostamatinib a Spleen Tyrosine Kinase Inhibitor
Authors: Muhammad Zain Farooq, Prasanth Lingamaneni, Saira Farid, Muhammad Saad Farooq, Ishaan Vohra, Asim Tameez ud din, Ankit Mangla
Journal: Blood (2019)
[18f]-(2S,4R)-4-Fluoroglutamine As a New Positron Emission Tomography Tracer in Multiple Myeloma
Authors: Nicola Giuliani, Silvia Valtorta, Martina Chiu, Denise Toscani, Andrea Sartori, Angela Coliva, Arianna Brevi, Stefania Battaglia, Emanuela Vicario, Giuseppe Taurino, Matteo Grioni, Francesca Ferlenghi, Livia Ruffini, Federica Vacondio, Franca Zanardi, Matteo Bellone, Rosa Maria Moresco, Ovidio Bussolati
Journal: Blood (2019)
Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML
Authors: Chezi Ganzel, Ron Ram, Alexander Gural, Ofir Wolach, Sharon Gino-Moor, Vladimir Vainstein, Boaz Nachmias, Arie Apel, Maya Koren-Michowitz, Oren Pasvolsky, Ronit Yerushalmi, Ivetta Danylesko, Yoseph Cohen, Galit Perets, Yakir Moshe, Miri Zektzer, Shay Yeganeh, Jacob M. Rowe, Yishai Ofran
Journal: Blood (2019)
Genome-Wide Analysis of 30 Burkitt Lymphomas Using High-Density SNP Arrays Reveals Frequent Cryptic Alterations Including Amplification of the microRNA 17-92 Locus.
Authors: Violaine Havelange, Ivan Théate, Evelyne Callet-Bauchu, Francine Mugneret, Lucienne Michaux, Carole Barin, Nicole Dastugue, Eric Lippert, Pascale Saussoy, Dominique Penther, Miikka Vikkula, Hélène A. Poirel
Journal: Blood (2007)